

For release 1st March 2020

Rosemont launches first licensed oral liquid Omeprazole

Rosemont the experts in licensed liquid medicines are pleased to announce the launch of Omeprazole Powder for Oral Suspension in 2mg/ml and 4mg/ml strengths.

Omeprazole in a liquid format has long been an unsatisfied need in patients with swallowing issues, previously having only been available as an unlicensed special.

The result of extensive research and development, Rosemont's Omeprazole Powder for Oral Suspension is the first PPI approved for use on a mg/kg basis, uniquely indicated in babies from 1 month and is licensed for use with PEG and NG tubes.

A major advance in formulation with an innovative new format, Omeprazole Powder for Oral Suspension has been developed in a patented pack that makes constitution easy.

All excipients have been carefully selected, the product contains no ethanol, sugar or propylene glycol. Our 2mg strength also includes a natural vanilla flavour to improve palatability for infants.

Howard Taylor, General Manager Rosemont Pharmaceuticals, commenting on the product launch said: *'I am delighted that following extensive research and development, Rosemont are able to bring to market this much requested, innovative product which fulfils a previously unmet need for both patients and healthcare professionals.'*

For more information please visit www.rosemontpharma.com.

Rosemont, making a happy difference to professionals and patients.

DTM162 DOP Jan 2020